CervoMed's cash runway is critically short, likely forcing a dilutive equity raise in Q3 2026. The planned Phase 3 DLB trial is entirely contingent on financing. Traders should monitor for an offering announcement and any partnership or grant updates. The EPS beat is overshadowed by the cash constraint.
Price Chart
Executive Summary
CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9M, providing runway only into September 2026. While EPS beat consensus by 12.2% ($-0.86 vs $-0.98), zero grant revenue and increased operating expenses highlight a critical need for near-term financing to initiate the planned Phase 3 DLB trial.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities: $12.9M as of March 31, 2026, down from $20.9M at year-end 2025.
- Net loss of $8.0M for Q1 2026 (vs $4.9M in Q1 2025), driven by $1.9M decrease in grant revenue and $0.9M increase in operating expenses.
- No grant revenue recognized in Q1 2026 vs $1.9M in Q1 2025.
- R&D expenses rose to $5.1M from $4.8M; G&A expenses rose to $3.0M from $2.4M.
- Cash runway projected only into September 2026, less than 4 months from filing date.
- Phase 3 DLB trial initiation subject to available financing.
- EPS beat consensus by 12.2% ($-0.86 actual vs $-0.98 estimate).
Financial Impact
Net loss widened $3.1M YoY; cash burn ~$8M/quarter; no revenue; runway ~3-4 months
Risk Factors
- Near-term financing risk — cash only into September 2026, likely requiring dilutive equity issuance.
- Phase 3 trial initiation dependent on securing adequate funding.
- No revenue stream; grant revenue has ended.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017637 |
| Exhibit: ex_964814.htm | 0001437749-26-017637 |
| Document: 0001437749-26-017637-index-headers.html | 0001437749-26-017637 |
| Document: 0001437749-26-017637-index.html | 0001437749-26-017637 |
| Document: 0001437749-26-017637.txt | 0001437749-26-017637 |
| 8-K Data (Synthetic) | 0001437749-26-017637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.22 (−1.11%) |
Oct 13, 2026 13d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.22 (−1.98%) |
Oct 9, 2026 16d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.22 (−11.35%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.22 (−10.28%) |
Aug 10, 2026 10w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.22 (−27.99%) |
Aug 4, 2026 11w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.22 (−20.54%) |
Aug 4, 2026 11w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.22 (−20.54%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.22 (+32.78%) |
Jul 6, 2026 15w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.22 (+34.94%) |
Jun 22, 2026 17w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.22 (+40.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers